MARKET

RNAC

RNAC

Cartesian
NASDAQ
5.85
-0.23
-3.78%
After Hours: 5.83 -0.02 -0.34% 16:18 03/27 EDT
OPEN
6.08
PREV CLOSE
6.08
HIGH
6.17
LOW
5.60
VOLUME
321.73K
TURNOVER
--
52 WEEK HIGH
16.62
52 WEEK LOW
5.60
MARKET CAP
155.08M
P/E (TTM)
-1.1661
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at RNAC last week (0316-0320)?
Weekly Report · 5d ago
Weekly Report: what happened at RNAC last week (0309-0313)?
Weekly Report · 03/16 09:20
RNAC’s Descartes-08 Moves Toward Phase 2 in Rare Muscle Disease: What Investors Should Watch
TipRanks · 03/12 16:34
Wedbush Reaffirms Their Buy Rating on Cartesian Therapeutics (RNAC)
TipRanks · 03/10 13:05
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Cartesian Therapeutics (RNAC) and Vertex Pharmaceuticals (VRTX)
TipRanks · 03/10 13:00
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Design Therapeutics (DSGN) and Cartesian Therapeutics (RNAC)
TipRanks · 03/10 12:40
Cartesian Therapeutics Price Target Maintained With a $38.00/Share by Wedbush
Dow Jones · 03/10 12:33
Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target
Benzinga · 03/10 12:23
More
About RNAC
Cartesian Therapeutics, Inc. is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. The Company’s lead asset, Descartes-08, is a chimeric antigen receptor T-cell therapy (CAR-T) entering Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-B-cell maturation antigen (BCMA) CAR-T being evaluated in a Phase 1 trial in patients with multiple myeloma. Descartes-08 is an autologous chimeric antigen receptor T-cell therapy product targeting B-cell maturation antigen in clinical development for generalized myasthenia gravis and systemic lupus erythematosus.

Webull offers Cartesian Therapeutics Inc stock information, including NASDAQ: RNAC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RNAC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RNAC stock methods without spending real money on the virtual paper trading platform.